		I
		111th CONGRESS
		1st Session
		H. R. 590
		IN THE HOUSE OF REPRESENTATIVES

			January 15, 2009
			Mr. Petri (for
			 himself and Mr. Conaway) introduced
			 the following bill; which was referred to the
			 Committee on Ways and
			 Means

		A BILL
		To amend the Internal Revenue Code of 1986 to provide
		  that reimbursements for costs of using passenger automobiles for charitable and
		  other organizations are excluded from gross income.

		1.Short titleThis Act may be cited as the
			 Charitable Driving Tax Relief Act of
			 2009.
		2.Mileage
			 reimbursements to charitable volunteers excluded from gross income
			(a)In
			 generalPart III of subchapter B of chapter 1 of the Internal
			 Revenue Code of 1986 is amended by inserting after section 139B the following
			 new section:

					139C.Mileage
				reimbursements to charitable volunteers
						(a)In
				generalGross income of an individual does not include amounts
				received, from an organization described in section 170(c), as reimbursement of
				operating expenses with respect to use of a passenger automobile for the
				benefit of such organization. The preceding sentence shall apply only to the
				extent that such reimbursement would be deductible under this chapter if
				section 274(d) were applied—
							(1)by using the
				standard business mileage rate established under such section, and
							(2)as if the
				individual were an employee of an organization not described in section
				170(c).
							(b)Application To
				volunteer services onlySubsection (a) shall not apply with respect
				to any expenses relating to the performance of services for
				compensation.
						(c)No double
				benefitSubsection (a) shall not apply with respect to any
				expenses if the individual claims a deduction or credit for such expenses under
				any other provision of this title.
						(d)Exemption from
				reporting requirementsSection 6041 shall not apply with respect
				to reimbursements excluded from income under subsection
				(a).
						.
			(b)Clerical
			 amendmentThe table of sections for part III of subchapter B of
			 chapter 1 of such Code is amended by inserting after the item relating to
			 section 139B the following new item:

						Sec. 139C. Reimbursement for use of
				passenger automobile for
				charity.

					.
			(c)Effective
			 dateThe amendments made by this section shall apply to taxable
			 years beginning after the date of the enactment of this Act.


116 HRES 824 IH: Expressing support for designation of the week beginning February 2, 2020, as “National Tribal Colleges and Universities Week”.
U.S. House of Representatives
2020-01-30
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IV116th CONGRESS2d SessionH. RES. 824IN THE HOUSE OF REPRESENTATIVESJanuary 30, 2020Mr. O'Halleran (for himself, Mr. Cole, Mr. Young, Mr. Kilmer, Mr. Armstrong, Mr. Luján, Ms. Haaland, Mr. Gallego, Mr. Peterson, and Mr. Johnson of South Dakota) submitted the following resolution; which was referred to the Committee on Oversight and ReformRESOLUTIONExpressing support for designation of the week beginning February 2, 2020, as National Tribal Colleges and Universities Week.

 Whereas there are 37 Tribal Colleges and Universities operating on more than 75 campuses in 16 States;
 Whereas Tribal Colleges and Universities are tribally chartered or federally chartered institutions of higher education and therefore have a unique relationship with the Federal Government;
 Whereas Tribal Colleges and Universities serve students from more than 230 federally recognized Indian Tribes;
 Whereas Tribal Colleges and Universities offer students access to knowledge and skills grounded in cultural traditions and values, including indigenous languages, which—
 (1)enhances Indian communities; and (2)enriches the United States as a Nation;
 Whereas Tribal Colleges and Universities provide access to high-quality postsecondary educational opportunities for—
 (1)American Indians; (2)Alaska Natives; and
 (3)other individuals that live in some of the most isolated and economically depressed areas in the United States;
 Whereas Tribal Colleges and Universities are accredited institutions of higher education that prepare students to succeed in the global and highly competitive workforce;
 Whereas Tribal Colleges and Universities have open enrollment policies, and approximately 15 percent of the students at Tribal Colleges and Universities are non-Indian individuals; and
 Whereas the collective mission and the considerable achievements of Tribal Colleges and Universities deserve national recognition: Now, therefore, be it

 That the House of Representatives— (1)supports the designation of National Tribal Colleges and Universities Week; and
 (2)calls on the people of the United States and interested groups to observe National Tribal Colleges and Universities Week with appropriate activities and programs to demonstrate support for Tribal Colleges and Universities.


109 HR 1720 IH: Raw Sewage Overflow Community Right-to-Know Act
U.S. House of Representatives
2005-04-20
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I
109th CONGRESS
1st Session
H. R. 1720
IN THE HOUSE OF REPRESENTATIVES

April 20, 2005
Mr. Bishop of New York introduced the following bill; which was referred to the Committee on Transportation and Infrastructure

A BILL
To amend the Federal Water Pollution Control Act to ensure that sewage treatment plants monitor for and report discharges of raw sewage, and for other purposes.

1.Short titleThis Act may be cited as the Raw Sewage Overflow Community Right-to-Know Act.
2.FindingsCongress finds the following:
(1)The Centers for Disease Control estimates that there are 7,100,000 cases of mild to moderate, and 560,000 cases of moderate to severe, infectious waterborne disease in the United States each year.
(2)Inadequately treated sewage is filled with bacteria, viruses, parasites, and worms that make people sick.
(3)People who ingest or inhale inadequately treated sewage can contract gastroenteritis, hepatitis, giardiasis, cryptosporidiosis, dysentery, and other gastrointestinal and respiratory diseases.
(4)Between 1,800,000 and 3,500,000 Americans become sick every year just from swimming in waters contaminated by sanitary sewer overflows.
(5)The loss of swimming opportunities (beach closings) due to pathogen contamination is valued at $1,000,000,000 to $2,000,000,000 annually in the United States.
(6)Economic losses due to swimming-related illnesses are estimated at $28,000,000,000 annually.
(7)Many sewer systems do not routinely monitor to detect sewer overflows or report those that do occur to environmental or public health agencies.
(8)Better monitoring, reporting, and public notification of sewer overflows would save millions of Americans from getting sick every year.
(9)Public health authorities are not routinely notified of sewer overflows that threaten public health.
3.DefinitionsSection 502 of the Federal Water Pollution Control Act (33 U.S.C. 1362) is amended by adding at the end the following:

(24)Sanitary sewer overflowThe term sanitary sewer overflow means an overflow, spill, release, or diversion of wastewater from a sanitary sewer system. Such term does not include combined sewer overflows or other discharges from the combined portions of a combined sewer system and does not include wastewater backups into buildings caused by a blockage or other malfunction of a building lateral that is privately owned. Such term includes overflows or releases of wastewater that reach waters of the United States, overflows or releases of wastewater that do not reach waters of the United States, and wastewater backups into buildings that are caused by blockages or flow conditions in a sanitary sewer other than a building lateral..
4.Monitoring, reporting, and public notification of sewer overflowsSection 402 of the Federal Water Pollution Control Act (33 U.S.C. 1342) is amended by adding at the end the following:

(r)Sanitary sewer overflows
(1)General requirementsNot later than 1 year after the date of enactment of this subsection, the owner or operator of a publicly owned treatment works (as defined in section 212) under a permit issued under this section—
(A)must institute and utilize a methodology, technology, or management program that will alert the owner or operator to the occurrence of a sanitary sewer overflow in a timely manner;
(B)must notify the public of a sanitary sewer overflow in any area where the overflow has the potential to affect human health;
(C)must notify the public as soon as practicable within 24 hours of the time the owner or operator becomes aware of the overflow;
(D)must immediately notify public health authorities and other affected entities, such as public water systems, of any sanitary sewer overflow that may imminently and substantially endanger human health;
(E)must provide to the Administrator or the State in the case of a State that has a permit program approved under this section either an oral or electronic report as soon as practicable within 24 hours of the time the owner or operator becomes aware of the overflow;
(F)must provide to the Administrator or the State, as the case may be, within 5 days of the time the owner or operator becomes aware of the overflow a written report describing—
(i)the magnitude, duration, and suspected cause of the overflow;
(ii)the steps taken or planned to reduce, eliminate, and prevent recurrence of the overflow; and
(iii)the steps taken or planned to mitigate the impact of the overflow;
(G)must report all sanitary sewer overflows to waters of the United States on its monthly discharge monitoring report to the Administrator or the State, as the case may be; and
(H)must report to the Administrator or the State, as the case may be, the total number of such overflows (including overflows that do not reach any waters of the United States) in a calendar year, including the details of how much wastewater was released per incident, the duration of each overflow, the location of the overflow and any potentially affected receiving waters, the responses taken to clean up the overflow, and the actions taken to mitigate impacts and avoid further sanitary sewer overflows at the site.
(2)Report to epaIf a State receives a report under paragraph (1)(H), the State shall report to the Administrator annually, in summary, the details of reported sanitary sewer overflows that occurred in that State..
5.Eligibility for assistanceSection 603(c) of the Federal Water Pollution Control Act (33 U.S.C. 1383(c)) is amended—
(1)by striking and the first place it appears; and
(2)by inserting after 320 of this Act the following: , and (4) for the implementation of requirements to monitor, report, and notify the public of sanitary sewer overflows under section 402.
6.Authorization of appropriationsSection 607 of the Federal Water Pollution Control Act (33 U.S.C. 1387) is amended by striking the following sums and all that follows through the period at the end and inserting $2,200,000,000 for each of fiscal years 2006 through 2012..


116 S1461 IS: Access to Infertility Treatment and Care Act
U.S. Senate
2019-05-14
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II116th CONGRESS1st SessionS. 1461IN THE SENATE OF THE UNITED STATESMay 14, 2019Mr. Booker (for himself and Mr. Menendez) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsA BILL To require health insurance coverage for the treatment of infertility.

 1.Short titleThis Act may be cited as the Access to Infertility Treatment and Care Act.
 2.FindingsCongress finds as follows: (1)Infertility is a medical disease recognized by the World Health Organization, the American Society for Reproductive Medicine, and the American Medical Association that affects men and women equally.
 (2)According to the Centers for Disease Control and Prevention, 1 in 8 couples have difficulty getting pregnant or sustaining a pregnancy.
 (3)Infertility affects a broad spectrum of prospective parents. No matter what race, religion, sexual orientation, or economic status one is, infertility does not discriminate.
 (4)According to the Centers for Disease Control and Prevention, 11 percent of women in the United States between the ages of 15 and 44 have difficulty getting pregnant or staying pregnant. Similarly, 9 percent of men in the United States between the ages of 15 and 44 experience infertility.
 (5)Infertility disproportionately affects individuals with particular health complications. For cancer patients and others who must undergo treatments such as chemotherapy, radiation therapy, hormone therapy, or surgery that are likely to harm the reproductive system and organs, fertility preservation becomes necessary.
 (6)Leading causes of infertility include chronic conditions and diseases of the endocrine or metabolic systems, such as primary ovarian insufficiency, polycystic ovarian syndrome, endometriosis, thyroid disorders, menstrual cycle defects, autoimmune disorders, hormonal imbalances, testicular disorders, and urological health issues. Other causes include structural problems or blockages within the reproductive system, exposure to infectious diseases, occupational or environmental hazards, or genetic influences.
 (7)Recent improvements in therapy and cryopreservation make pregnancy possible for more people than in past years.
 (8)Like all other diseases, infertility and its treatments should be covered by health insurance. (9)A 2017 national survey of employer-sponsored health plans found that 44 percent of employers with at least 500 employees did not cover infertility services, and 25 percent of companies with 20,000 or more employees did not cover infertility services.
 (10)Coverage for infertility services under State Medicaid programs is limited. The Medicaid programs of only 5 States provide diagnostic testing for women and men in all of their program eligibility pathways; the Medicaid program of only one State provides coverage for certain medications for women experiencing infertility; and no State Medicaid programs cover intrauterine insemination or in vitro fertilization.
 (11)States that do not require private insurance coverage of assisted reproductive technology have higher rates of multiple births.
 (12)The ability to have a family should not be denied to anyone on account of a lack of insurance coverage for medically necessary treatment.
			3.Standards relating to benefits for treatment of infertility and prevention of iatrogenic
			 infertility
 (a)In generalPart A of title XXVII of the Public Health Service Act (42 U.S.C. 300gg et seq.) is amended by inserting after section 2728 the following:

					2729A.Standards relating to benefits for treatment of infertility and prevention of iatrogenic
			 infertility
 (a)In generalA group health plan or a health insurance issuer offering group or individual health insurance coverage shall ensure that such plan or coverage provides coverage for—
 (1)the treatment of infertility, including nonexperimental assisted reproductive technology procedures, if such plan or coverage provides coverage for obstetrical services; and
 (2)standard fertility preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic infertility.
 (b)DefinitionsIn this section: (1)the term assisted reproductive technology means treatments or procedures that involve the handling of human egg, sperm, and embryo outside of the body with the intent of facilitating a pregnancy, including in vitro fertilization, egg, embryo, or sperm cryopreservation, egg or embryo donation, and gestational surrogacy;
 (2)the term infertility means a disease, characterized by the failure to establish a clinical pregnancy— (A)after 12 months of regular, unprotected sexual intercourse; or
 (B)due to a person's incapacity for reproduction either as an individual or with his or her partner, which may be determined after a period of less than 12 months of regular, unprotected sexual intercourse, or based on medical, sexual and reproductive history, age, physical findings, or diagnostic testing; and
 (3)the term iatrogenic infertility means an impairment of fertility due to surgery, radiation, chemotherapy, or other medical treatment.
							(c)Required coverage
 (1)Coverage for infertilitySubject to paragraph (3), a group health plan and a health insurance issuer offering group or individual health insurance coverage that includes coverage for obstetrical services shall provide coverage for treatment of infertility determined appropriate by the treating physician, including, as appropriate, ovulation induction, egg retrieval, sperm retrieval, artificial insemination, in vitro fertilization, genetic screening, intracytoplasmic sperm injection, and any other non-experimental treatment, as determined by the Secretary in consultation with appropriate professional and patient organizations such as the American Society for Reproductive Medicine, RESOLVE: The National Infertility Association, and the American College of Obstetricians and Gynecologists.
 (2)Coverage for iatrogenic infertilityA group health plan and a health insurance issuer offering group or individual health insurance coverage shall provide coverage of fertility preservation services for individuals who undergo medically necessary treatment that may cause iatrogenic infertility, as determined by the treating physician, including cryopreservation of gametes and other procedures, as determined by the Secretary, consistent with established medical practices and professional guidelines published by professional medical organizations, including the American Society of Clinical Oncology and the American Society for Reproductive Medicine.
 (3)Limitation on coverage of assisted reproductive technologyA group health plan and a health insurance issuer offering group or individual health insurance coverage shall provide coverage for assisted reproductive technology as required under paragraph (1) if—
 (A)the individual is unable to bring a pregnancy to a live birth through minimally invasive infertility treatments, as determined appropriate by the treating physician, with consideration given to participant's or beneficiary's specific diagnoses or condition for which coverage is available under the plan or coverage; and
 (B)the treatment is performed at a medical facility that— (i)conforms to the standards of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology; and
 (ii)is in compliance with any standards set by an appropriate Federal agency. (d)LimitationCost-sharing, including deductibles and coinsurance, or other limitations for infertility and services to prevent iatrogenic infertility may not be imposed with respect to the services required to be covered under subsection (c) to the extent that such cost-sharing exceeds the cost-sharing applied to similar services under the group health plan or health insurance coverage or such other limitations are different from limitations imposed with respect to such similar services.
 (e)ProhibitionsA group health plan and a health insurance issuer offering group or individual health insurance coverage may not—
 (1)provide incentives (monetary or otherwise) to a participant or beneficiary to encourage such participant or beneficiary not to be provided infertility treatments or fertility preservation services to which such participant or beneficiary is entitled under this section or to providers to induce such providers not to provide such treatments to qualified participants or beneficiaries;
 (2)prohibit a provider from discussing with a participant or beneficiary infertility treatments or fertility preservation technology or medical treatment options relating to this section; or
 (3)penalize or otherwise reduce or limit the reimbursement of a provider because such provider provided infertility treatments or fertility preservation services to a qualified participant or beneficiary in accordance with this section.
 (f)Rule of constructionNothing in this section shall be construed to require a participant or beneficiary to undergo infertility treatments or fertility preservation services.
 (g)NoticeA group health plan and a health insurance issuer offering group or individual health insurance coverage shall provide notice to each participant and beneficiary under such plan regarding the coverage required by this section in accordance with regulations promulgated by the Secretary. Such notice shall be in writing and prominently positioned in any literature or correspondence made available or distributed by the plan or issuer and shall be transmitted—
 (1)in the next mailing made by the plan or issuer to the participant or beneficiary; (2)as part of any yearly informational packet sent to the participant or beneficiary; or
 (3)not later than January 1, 2020, whichever is earlier.(h)Level and type of reimbursementsNothing in this section shall be construed to prevent a group health plan or a health insurance issuer offering group or individual health insurance coverage from negotiating the level and type of reimbursement with a provider for care provided in accordance with this section..
 (b)Conforming amendmentSection 2724(c) of the Public Health Service Act (42 U.S.C. 300gg–23(c)) is amended by striking section 2704 and inserting sections 2704 and 2708. (c)Effective dates (1)In generalThe amendments made by subsections (a) and (b) shall apply for plan years beginning on or after the date that is 6 months after the date of enactment of this Act.
				(2)Collective bargaining exception
 (A)In generalIn the case of a group health plan maintained pursuant to one or more collective bargaining agreements between employee representatives and one or more employers ratified before the date of enactment of this Act, the amendments made by subsection (a) shall not apply to plan years beginning before the later of—
 (i)the date on which the last collective bargaining agreements relating to the plan terminates (determined without regard to any extension thereof agreed to after the date of enactment of this Act), or
 (ii)the date occurring 6 months after the date of the enactment of this Act. (B)ClarificationFor purposes of subparagraph (A), any plan amendment made pursuant to a collective bargaining agreement relating to the plan which amends the plan solely to conform to any requirement added by subsection (a) shall not be treated as a termination of such collective bargaining agreement.
					4.Federal Employees Health Benefits Program
 (a)In generalSection 8902 of title 5, United States Code, is amended by adding at the end the following:  (p)Coverage for diagnosis and treatment of infertility and prevention of iatrogenic infertility (1)DefinitionsIn this subsection, the terms infertility and iatrogenic infertility have the meanings given those terms in section 2729A of the Public Health Service Act.
 (2)Required coverageA contract under this chapter shall provide, in a manner consistent with section 2729A of the Public Health Service Act—
 (A)coverage for the diagnosis and treatment of infertility, including nonexperimental assisted reproductive technology procedures, if such contract covers obstetrical benefits; and
 (B)coverage for standard fertility preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic infertility.
 (3)CostCoverage for the diagnosis or treatment of infertility and fertility preservation services under a health benefits plan described in section 8903 or 8903a may not be subject to any copayment or deductible greater than the copayment or deductible, respectively, applicable to obstetrical benefits under the plan.
 (4)PreemptionSubsection (m)(1) shall not, with respect to a contract under this chapter, prevent the inclusion of any terms that, under paragraph (2) of this subsection, are required by reason of section 2729A of the Public Health Service Act..
 (b)Effective dateThe amendment made by subsection (a) shall apply with respect to any contract entered into or renewed for a contract year beginning on or after the date that is 180 days after the date of enactment of this Act, and any health benefits plan offered under such a contract.
			5.Benefits for treatment of infertility and prevention of  iatrogenic infertility under the TRICARE
			 program
 (a)In generalChapter 55 of title 10, United States Code, is amended by adding at the end the following new section:

					1110c.Obstetrical and infertility benefits
 (a)In generalAny health care plan under this chapter shall provide, in a manner consistent with section 2729A of the Public Health Service Act—
 (1)coverage for the diagnosis and treatment of infertility, including nonexperimental assisted reproductive technology procedures, if such plan covers obstetrical benefits; and
 (2)coverage for standard fertility preservation services when a medically necessary treatment may directly or indirectly cause iatrogenic infertility.
 (b)CopaymentThe Secretary of Defense shall establish cost-sharing requirements for the coverage of diagnosis and treatment of infertility and fertility preservation services described in subsection (a) that are consistent with the cost-sharing requirements applicable to health plans and health insurance coverage under section 2729A(d) of the Public Health Service Act.
 (c)RegulationsThe Secretary of Defense shall prescribe any regulations necessary to carry out this section. (d)DefinitionsIn this section, the terms infertility and iatrogenic infertility have the meanings given those terms in section 2729A of the Public Health Service Act..
 (b)Clerical amendmentThe table of sections at the beginning of chapter 55 of such title is amended by adding at the end the following new item:
				1110c. Obstetrical and infertility benefits..
			6.Treatment of infertility and prevention of iatrogenic infertility for veterans and spouses or
			 partners
			 of veterans
 (a)In generalSubchapter II of chapter 17 of title 38, United States Code, is amended by adding at the end the following new section:

					1720J.Infertility treatment for veterans and spouses or partners
			 of veterans.
 (a)In generalThe Secretary shall furnish treatment for infertility and fertility preservation services, including through the use of assisted reproductive technology, to a veteran or a spouse or partner of a veteran if the veteran, and the spouse or partner of the veteran, as applicable, apply jointly for such treatment and counseling through a process prescribed by the Secretary for purposes of this section.
 (b)Infertility definedIn this section, the terms infertility and iatrogenic infertility have the meanings given those terms in section 2729A of the Public Health Service Act.. (b)Clerical amendmentThe table of sections at the beginning of chapter 17 of such title is amended by inserting after the item relating to section 1720I the following new item:
				1720J. Infertility treatment for veterans and spouses or partners
			 of veterans..
 (c)RegulationsNot later than 18 months after the date of the enactment of this Act, the Secretary of Veterans Affairs shall prescribe regulations to carry out section 1720J of title 38, United States Code, as added by subsection (a).
			7.Requirement for State Medicaid plans to provide medical assistance for treatment of infertility and
			 prevention of iatrogenic infertility
 (a)In generalSection 1905 of the Social Security Act (42 U.S.C. 1396d) is amended— (1)in subsection (a)(4)—
 (A)by striking ; and (D) and inserting ; (D); and (B)by inserting before the semicolon at the end the following: ; and (E) services and supplies to treat infertility and prevent iatrogenic infertility (as such terms are defined in section 2729A(b) of the Public Health Service Act) in accordance with subsection (ff); and
 (2)by adding at the end the following new subsection:  (ff)Requirements for coverage of infertility treatment and prevention of iatrogenic infertilityFor purposes of subsection (a)(4)(E), a State shall ensure that the medical assistance provided under the State plan (or waiver of such plan) for treatment of infertility and fertility preservation services complies with the requirements and limitations of section 2729A(c) of the Public Health Service Act in the same manner as such requirements and limitations apply to health insurance coverage offered by a group health plan or health insurance issuer..
				(b)No cost sharing for infertility treatment
 (1)In generalSubsections (a)(2)(D) and (b)(2)(D) of section 1916 of the Social Security Act (42 U.S.C. 1396o(a)(2)(D)) are amended by inserting , services and supplies to treat infertility and provide fertility preservation services described in section 1905(a)(4)(E) before , or each place it appears.
 (2)Application to alternative cost sharingSection 1916A(b)(3)(B)(vii) of the Social Security Act (42 U.S.C. 1396o–1(b)(3)(B)(vii)) is amended by inserting  and services and supplies to treat infertility and provide fertility preservation described in section 1905(a)(4)(E) before the period.
 (c)Presumptive eligibility for infertility treatmentSection 1920C of the Social Security Act (42 U.S.C. 1396r–1c) is amended— (1)in the section heading, by inserting and infertility treatment after family planning services;
 (2)in subsection (a)— (A)by striking State plan and inserting A State plan;
 (B)by striking 1905(a)(4)(C) and inserting section 1905(a)(4)(C), services and supplies to treat infertility and prevent iatrogenic infertility described in section 1905(a)(4)(E),; and
 (C)by inserting or in conjunction with an infertility treatment service in an infertility treatment setting before the period. (d)Inclusion in benchmark coverageSection 1937(b) of the Social Security Act (42 U.S.C. 1396u–7(b)) is amended by adding at the end the following new paragraph:

 (8)Coverage of infertility treatment and prevention of iatrogenic infertilityNotwithstanding the previous provisions of this section, a State may not provide for medical assistance through enrollment of an individual with benchmark coverage or benchmark-equivalent coverage under this section unless such coverage includes medical assistance for services and supplies to treat infertility and provide fertility preservation described in section 1905(a)(4)(E) in accordance with such section..
			(e)Effective date
 (1)In generalExcept as provided in paragraph (2), the amendments made by this section shall take effect on October 1, 2020.
 (2)Delay permitted if State legislation requiredIn the case of a State plan approved under title XIX of the Social Security Act which the Secretary of Health and Human Services determines requires State legislation (other than legislation appropriating funds) in order for the plan to meet the additional requirement imposed by this section, the State plan shall not be regarded as failing to comply with the requirements of such title solely on the basis of the failure of the plan to meet such additional requirement before the first day of the first calendar quarter beginning after the close of the first regular session of the State legislature that ends after the 1-year period beginning with the date of the enactment of this section. For purposes of the preceding sentence, in the case of a State that has a 2-year legislative session, each year of the session is deemed to be a separate regular session of the State legislature.


110 HRES 654 EH: Congratulating the Phoenix Mercury for

U.S. House of Representatives
2007-10-09
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

		IV
		110th CONGRESS
		1st Session
		H. RES. 654
		In the House of Representatives, U.
		  S.,

			October 9, 2007

		RESOLUTION
		Congratulating the Phoenix Mercury for
		  winning the 2007 Women’s National Basketball Association (WNBA)
		  Championship.

		Whereas, on September 16, 2007, the Phoenix Mercury won
			 the 2007 Women’s National Basketball Association (WNBA) Championship after
			 cruising to victory over the defending champion Detroit Shock with a strong
			 final score of 108 to 92 in the fifth and deciding game of the series;
		Whereas this is the Mercury’s first WNBA Championship
			 since the team’s formation in 1997 as one of the WNBA’s original 8
			 teams;
		Whereas the Mercury is the first team to win the WNBA
			 Championship on the road;
		Whereas, after only 2 seasons as head coach, the superb
			 leadership and up-tempo style of Coach Paul Westhead guided the Mercury to this
			 Championship;
		Whereas, after only 2 years in the WNBA, Cappie Pondexter
			 scored 26 points in the final game of the series and was chosen as the Most
			 Valuable Player for the WNBA Finals;
		Whereas Cappie Pondexter was ably assisted by Penny
			 Taylor, who scored 30 points, and Diana Taurasi, who scored 17 points, in
			 addition to outstanding efforts from teammates Tangela Smith, Kelly Miller,
			 Kelly Mazzante, Kelly Schumacher, Belinda Snell, Olympia Scott, Jennifer
			 Derevjanik, and Jennifer Lacy;
		Whereas this impressive win makes Coach Paul Westhead the
			 first coach in history to capture both the NBA Championship and WNBA
			 Championship;
		Whereas the Mercury entered the WNBA Playoffs with their
			 best record in franchise history at 23–11 and after 6 years of having missed
			 inclusion in the Playoffs;
		Whereas there was no doubt who was taking control of the
			 final game as the Mercury led by as many as 14 points in the first quarter,
			 posted an impressive record by shooting 73.3 percent for the first quarter, and
			 led by as many as 18 points in the second quarter; and
		Whereas the city of Phoenix joins the Phoenix Mercury
			 owner, Robert Sarver, in taking enormous pride in the accomplishment of this
			 outstanding team: Now, therefore, be it

		That the House of Representatives
			 congratulates the Phoenix Mercury and Coach Paul Westhead for winning the 2007
			 Women’s National Basketball Association Championship.

			Lorraine C. Miller,
			Clerk.


		I
		111th CONGRESS
		1st Session
		H. R. 3635
		IN THE HOUSE OF REPRESENTATIVES

			September 23, 2009
			Mr. Cao introduced
			 the following bill; which was referred to the
			 Committee on Transportation and
			 Infrastructure

		A BILL
		To amend the Robert T. Stafford Disaster Relief and
		  Emergency Assistance Act to improve Federal assistance with respect to
		  disasters, and for other purposes.

		1.Short titleThis Act may be cited as the
			 Disaster Relief and Recovery Development Act of
			 2009.
		2.Ability to
			 provide disaster information to individuals with limited English
			 proficiency
			(a)StudyThe Comptroller General of the United
			 States shall conduct a study on the ability of existing alert and warning
			 systems to provide information relating to disasters to individuals with
			 limited English proficiency.
			(b)ReportNot later than one year after the date of
			 enactment of this Act, the Comptroller General shall submit to Congress a
			 report on the results of the study conducted under subsection (a). The report
			 shall include recommendations with respect to any additional resources
			 necessary to adequately provide information relating to disasters to
			 individuals with limited English proficiency.
			3.Review of
			 regulations and policies
			(a)In
			 generalNot later than one
			 year after the date of enactment of this Act, the President shall review
			 regulations and policies relating to Federal disaster assistance to eliminate
			 regulations the President determines are no longer relevant, to harmonize
			 contradictory regulations, and to simplify and expedite disaster recovery and
			 assistance.
			(b)ReportNot later than 18 months after the date of
			 enactment of this Act, the President shall transmit to Congress a report
			 describing changes made to regulations as a result of the review required under
			 subsection (a), together with any legislative recommendations relating
			 thereto.
			4.Issuance of
			 regulations relating to eligible costNot later than six months after the date of
			 enactment of this Act, the President shall issue and begin implementation of
			 the regulations required under section 406(e)(3)(C) of the Robert T. Stafford
			 Disaster Relief and Emergency Assistance Act (42 U.S.C. 5172(e)(3)(C)) to
			 provide for cost estimation procedures that expedite recovery and to reduce the
			 costs and time for completion of recovery projects through the creation of
			 financial and performance incentives.
		5.Use of financial
			 assistance to disseminate information regarding cost-effective mitigation
			 technologiesSection 203(e)(2)
			 of the Robert T. Stafford Disaster Relief and Emergency Assistance Act (42
			 U.S.C. 5133(e)(2)) is amended by striking 10 percent and
			 inserting 15 percent.
		6.Recovery
			 responsibilities
			(a)Functions of
			 Federal coordinating officerSection 302(b) of the Robert T. Stafford
			 Disaster Relief and Emergency Assistance Act (42 U.S.C. 5143(b)) is
			 amended—
				(1)in paragraph (3)
			 by striking and at the end;
				(2)by redesignating
			 paragraph (4) as paragraph (6); and
				(3)by inserting after
			 paragraph (3) the following:

						(4)not later than one month after the date of
				the declaration of a major disaster or emergency, make an initial appraisal of
				the types of recovery assistance needed;
						(5)coordinate with
				State government officials the establishment of detailed short-term and
				long-term recovery plans and methods for implementation of such plans;
				and
						.
				(b)Emergency
			 support, response, and recovery teamsSection 303 of such Act (42
			 U.S.C. 5144) is amended—
				(1)in the section
			 heading by striking support
			 and response and inserting support, response, and
			 recovery; and
				(2)by adding at the
			 end the following:

						(c)Emergency
				recovery teams
							(1)EstablishmentIn carrying out subsection (a), the
				President, acting through the Administrator of the Federal Emergency Management
				Agency, shall establish—
								(A)at a minimum 3
				national recovery teams;
								(B)sufficient
				regional recovery teams, including Regional Office strike teams under section
				507 of the Homeland Security Act of 2002; and
								(C)other recovery
				teams as may be necessary to meet the incident management responsibilities of
				the Federal Government.
								(2)Target
				capability levelThe
				Administrator shall ensure that specific target capability levels, as defined
				pursuant to the guidelines established under section 646(a) of the Post-Katrina
				Emergency Management Reform Act of 2006, are established for Federal emergency
				recovery teams.
							(3)PersonnelThe President, acting through the
				Administrator, shall ensure that the Federal emergency recovery teams consist
				of adequate numbers of properly planned, organized, equipped, trained, and
				exercised personnel to achieve the established target capability levels. Each
				emergency recovery team shall work in coordination with State and local
				officials and onsite personnel associated with a particular incident.
							(4)Readiness
				ReportingThe Administrator shall evaluate team readiness on a
				regular basis and report team readiness levels in the report required under
				section 652(a) of the Post-Katrina Emergency Management Reform Act of
				2006.
							.
				7.Federal
			 interagency disaster recovery task forceTitle III of the Robert T. Stafford Disaster
			 Relief and Emergency Assistance Act (42 U.S.C. 5141 et seq.) is amended by
			 adding at the end the following:

				327.Federal
				interagency disaster recovery task force
					(a)EstablishmentThe President shall establish a Federal
				interagency disaster recovery task force (hereinafter referred to in this
				section as the task force) to carry out the following:
						(1)Identify, maintain
				a catalogue of, and submit to Congress at least twice each year a report
				describing the Federal programs that may be used to assist in recovery efforts
				after a major disaster or emergency.
						(2)Ensure
				communication, before and after major disasters and emergencies, between the
				Federal departments and agencies determined by the President to administer the
				Federal programs referred to in paragraph (1).
						(b)ChairpersonThe
				Administrator of the Federal Emergency Management Agency shall serve as the
				chairperson of the task force.
					(c)MembershipThe
				task force shall include a representative of each Federal department and agency
				determined by the President to administer a program that may be used to assist
				in recovery efforts after a major disaster or emergency.
					(d)Meeting
				frequencyThe task force shall meet at least four times each
				year.
					.
		8.Repair,
			 restoration, and replacement of damaged facilitiesSection
			 406(a) of the Robert T. Stafford Disaster Relief and Emergency Assistance Act
			 (42 U.S.C. 5172(a)) is amended—
			(1)in paragraph (4)
			 by striking $20,000,000 and inserting $5,000,000;
			 and
			(2)by adding at the
			 end the following:

					(5)Contribution
				status reportsNot less
				frequently than every 180 days, the President shall transmit to Congress a
				report on the status of applications, obligations, and contributions under this
				section with respect to each major disaster for which, on the date of the
				transmission of such report, a contribution is eligible to be requested or made
				under this
				section.
					.
			9.Special rule for
			 certain major disastersSection 406 of the Robert T. Stafford
			 Disaster Relief and Emergency Assistance Act (42 U.S.C. 5172) is amended by
			 adding at the end the following:

				(f)Special rule for
				certain major disasters
					(1)Consolidation of
				fundsNotwithstanding
				subsection (a)(1), if the President determines that there is extensive and
				widespread damage and destruction resulting from a major disaster, the
				President may allow a State or local government or a private nonprofit
				facility, as the case may be, to consolidate contributions received as a lump
				sum payment to repair, restore, reconstruct, or replace more than one public
				facility. A State or local government and a private nonprofit facility may
				choose whether or not to repair, restore, reconstruct, or replace one or more
				of such facilities after assessing the need for such facilities after such
				major disaster.
					(2)Federal
				shareNotwithstanding subsection (c)(1)(A), the Federal share for
				a public facility shall be an amount equal to 100 percent of the Federal
				estimate of the cost of repairing, restoring, reconstructing, or replacing the
				facilities and of management expenses.
					.


109 HRES 421 IH: Commending the Biotechnology Industry Organization, the world’s largest biotechnology organization, for a successful annual convention in Philadelphia, Pennsylvania.
U.S. House of Representatives
2005-07-29
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IV
109th CONGRESS
1st Session
H. RES. 421
IN THE HOUSE OF REPRESENTATIVES

July 29, 2005
Ms. Schwartz of Pennsylvania (for herself, Mr. Dent, Mr. Brady of Pennsylvania, Mr. Payne, Mr. Fitzpatrick of Pennsylvania, Mr. Sherwood, Mr. Castle, Mr. Holt, Mr. Fattah, Mr. Pascrell, Mr. Murtha, Mr. Larson of Connecticut, Mr. Doyle, Mr. Holden, Mr. Kanjorski, Mrs. McCarthy, Mr. Mollohan, Mr. Rothman, Mr. Menendez, Mr. Kind, Mrs. Tauscher, Mr. Crowley, Mrs. Davis of California, Mr. Gerlach, Mr. Pallone, Mr. Bishop of New York, Ms. Harman, Mr. Higgins, Mr. Kildee, Ms. Solis, Ms. Velázquez, Mrs. Napolitano, Ms. Roybal-Allard, Mr. Weldon of Pennsylvania, Ms. Berkley, Mr. Cardoza, Mr. Smith of Washington, Mr. Carnahan, Mr. Cleaver, Mr. Schiff, Ms. Hooley, Ms. DeGette, Mr. Moore of Kansas, Mr. Van Hollen, Mr. Ford, Mr. Davis of Tennessee, Mr. Scott of Virginia, Mr. Olver, Mr. Chandler, Mr. Al Green of Texas, Mr. LoBiondo, and Mr. Frelinghuysen) submitted the following resolution; which was referred to the Committee on Government Reform

RESOLUTION
Commending the Biotechnology Industry Organization, the world’s largest biotechnology organization, for a successful annual convention in Philadelphia, Pennsylvania.

Whereas the Biotechnology Industry Organization (BIO), the world’s largest biotechnology organization, provides advocacy, business development, and communications services for more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and 31 other nations;
Whereas biotechnology research expands the boundaries of science to benefit mankind by providing for better healthcare, enhanced agriculture, and a cleaner and safer environment;
Whereas the convergence of systems biology, genomics, infomatics, proteomics, nanotechnology, and personalized medicine bring us to the threshold of a new era;
Whereas biotechnology therapeutics are used to treat many diseases, including anemia, cystic fibrosis, growth deficiency, rheumatoid arthritis, hemophilia, hepatitis, transplant rejection, leukemia, and other cancers;
Whereas there are more than 300 biotech drug products and vaccines currently in clinical trials targeting more than 200 diseases, including various cancers, Alzheimer’s disease, heart disease, diabetes, multiple sclerosis, AIDS, and arthritis;
Whereas biotechnology is responsible for hundreds of medical diagnostic tests that keep the blood supply safe from the AIDS virus and detect other conditions early enough to be successfully treated;
Whereas environmental biotechnology products make it possible to clean up hazardous waste more efficiently by harnessing pollution-eating microbes without the use of caustic chemicals;
Whereas industrial biotechnology applications have led to cleaner processes that produce less waste and use less energy and water in such industrial sectors as chemicals, pulp and paper, textiles, food, energy, and metals and minerals;
Whereas industrial biotechnology also enables its users to harness enzymes to convert plant waste to fuel and to biodegradable plastics, reducing our dependence on foreign oil;
Whereas agriculture biotechnology allows its users to produce more and more healthful foods, on a fixed amount of arable land, in a more efficient manner, and these breakthroughs reduce soil tillage, fossil fuel use, and runoff of agricultural pesticides into our lakes, streams, and oceans;
Whereas BIO brought together more than 18,700 people from 56 countries and all 50 States at its annual international convention in Philadelphia, Pennsylvania, from June 19 through June 22, 2005;
Whereas the Commonwealth of Pennsylvania, the State of Delaware, and the State of New Jersey co-hosted the convention, known as the BIO 2005 Annual International Convention;
Whereas more than 300 volunteers from this tri-State region and hundreds of employees of the City of Philadelphia contributed to the Convention’s success;
Whereas the immediate economic impact of the BIO 2005 Annual International Convention on the City of Philadelphia, including its hotels, restaurants, and taxi operators, is estimated at more than $35 million;
Whereas the Convention put the local life-sciences community on the map globally; and
Whereas the BIO 2005 Annual International Convention will allow for further collaboration, advancement, and development within the field of biotechnology: Now, therefore, be it

That the House of Representatives commends the Biotechnology Industry Organization for a successful 2005 Annual International Convention at the Pennsylvania Convention Center in the City of Philadelphia.


116 SRES 727 IS: Designating September 2020 as “National Ovarian Cancer Awareness Month”.
U.S. Senate
2020-09-30
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

III116th CONGRESS2d SessionS. RES. 727IN THE SENATE OF THE UNITED STATESSeptember 30 (legislative day, September 29), 2020Ms. Stabenow (for herself, Ms. Murkowski, Mrs. Feinstein, Mr. Brown, Mr. Blumenthal, Mr. Peters, Mr. Menendez, Mr. Van Hollen, and Mrs. Capito) submitted the following resolution; which was referred to the Committee on the JudiciaryRESOLUTIONDesignating September 2020 as National Ovarian Cancer Awareness Month.Whereas ovarian cancer is the fifth leading cause of cancer deaths in women in the United States and accounts for more deaths than any other cancer of the female reproductive system;Whereas, in the United States, a woman’s lifetime risk of being diagnosed with ovarian cancer is about 1 in 78;Whereas the American Cancer Society estimates 21,750 new cases of ovarian cancer will be diagnosed in 2020 and 13,940 people will die from the disease nationwide;Whereas the 5-year survival rate for ovarian cancer is 46.5 percent, and survival rates vary greatly depending on the stage of diagnosis;Whereas the 5-year survival rate for ovarian cancer is over 90 percent for women diagnosed in early stages;Whereas, while the mammogram can detect breast cancer and the Pap smear can detect cervical cancer, there is no reliable early detection test for ovarian cancer;Whereas, in June 2007, the first national consensus statement on ovarian cancer symptoms was developed to provide consistency in describing symptoms and make it easier for women to learn and remember those symptoms; Whereas too many people remain unaware that the symptoms of ovarian cancer often include bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, urinary symptoms, and several other vague symptoms that are often easily confused with other diseases;Whereas improved awareness of the symptoms of ovarian cancer by the public and health care providers can lead to a quicker diagnosis;Whereas the lack of an early detection test for ovarian cancer, combined with its vague symptoms, mean that approximately 80 percent of cases of ovarian cancer are detected at an advanced stage;Whereas all women are at risk for ovarian cancer, but approximately 20 percent of women who are diagnosed with ovarian cancer have a hereditary predisposition to ovarian cancer, which places them at even higher risk;Whereas scientists and physicians have uncovered changes in the BRCA genes that some women inherit from their parents, which may make those women 30 times more likely to develop ovarian cancer;Whereas the family history of a woman has been found to play an important role in accurately assessing a woman's risk of developing ovarian cancer, and medical experts believe that family history should be taken into consideration during the annual well-woman visit of any woman;Whereas women who know that they are at high risk of ovarian cancer may undertake prophylactic measures to help reduce the risk of developing this disease;Whereas guidelines issued by the National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend that all individuals diagnosed with ovarian cancer receive genetic counseling and genetic testing regardless of their family history;Whereas studies consistently show that compliance with such guidelines is alarmingly low, with recently published National Cancer Institute-funded research finding that in 2013 and 2014, only 1/3 of ovarian cancer survivors had undergone such testing;Whereas, according to a 2016 consensus report by the National Academy of Medicine, there remain surprising gaps in the fundamental knowledge about and understanding of ovarian cancer across all aspects of the disease;Whereas ongoing investments in ovarian cancer research and education and awareness efforts are critical to closing these gaps and improving survivorship for women with ovarian cancer;Whereas, each year during the month of September, the Ovarian Cancer Research Alliance (OCRA) and its community partners hold a number of events to increase public awareness of ovarian cancer and its symptoms; andWhereas September 2020 should be designated as National Ovarian Cancer Awareness Month to increase public awareness of ovarian cancer: Now, therefore, be itThat the Senate—(1)designates September 2020 as National Ovarian Cancer Awareness Month; and(2)supports the goals and ideals of National Ovarian Cancer Awareness Month.


		III
		110th CONGRESS
		1st Session
		S. RES. 350
		IN THE SENATE OF THE UNITED STATES

			October 17, 2007
			Mr. Hatch (for himself,
			 Mr. Bennett, Mrs. Dole, and Mr.
			 Burr) submitted the following resolution; which was considered and
			 agreed to

		RESOLUTION
		Honoring the achievements of Mario R.
		  Capecchi, Sir Martin J. Evans, and Oliver Smithies, winners of the 2007 Nobel
		  Prize in Physiology or Medicine.

		Whereas Mario R. Capecchi was born in Italy in 1937 and
			 earned a PhD in biophysics from Harvard University in 1967;
		Whereas Sir Martin J. Evans was born in Great Britain in
			 1941 and earned a PhD in anatomy and embryology from University College in
			 London in 1969;
		Whereas Oliver Smithies was born in Great Britain in 1925
			 and earned a PhD in biochemistry from Oxford University in 1951;
		Whereas Mario Capecchi currently serves as Distinguished
			 Professor of Human Genetics and Biology at the University of Utah School of
			 Medicine;
		Whereas Sir Martin J. Evans currently serves as the
			 Professor of Mammalian Genetics and Director of the School of Biosciences at
			 Cardiff University in Wales;
		Whereas Oliver Smithies currently serves as an Excellence
			 Professor of Pathology and Laboratory Medicine at the University of North
			 Carolina at Chapel Hill;
		Whereas Mario R. Capecchi, Sir Martin J. Evans, and Oliver
			 Smithies have made a series of discoveries concerning embryonic stem cells and
			 deoxyribonucleic acid (DNA) recombination in mammals that have led to the
			 creation of gene targeting in mice, a powerful technology that is now being
			 used in all areas of biomedicine;
		Whereas gene targeting technology has been used in
			 experiments that have successfully isolated genes in order to determine their
			 roles in embryonic development, adult physiology, aging, and disease;
		Whereas gene targeting has produced more than 500
			 different mouse models of human disorders, including cardiovascular and neuron
			 degenerative diseases, diabetes, and cancer; and
		Whereas, on October 8, 2007, Mario R. Capecchi, Sir Martin
			 J. Evans, and Oliver Smithies were awarded the Nobel Prize in Physiology or
			 Medicine for their discoveries of principles for introducing specific gene
			 modifications in mice by the use of embryonic stem cells: Now, therefore, be
			 it

		That the Senate—
			(1)honors and
			 recognizes the scientific work and achievements of Mario R. Capecchi, Sir
			 Martin J. Evans, and Oliver Smithies; and
			(2)congratulates
			 Mario R. Capecchi, Sir Martin J. Evans, and Oliver Smithies for their receipt
			 of the Nobel Prize in Physiology or Medicine.


117 HR 2031 IH: To amend the Internal Revenue Code of 1986 to encourage the transfer of intangible property from controlled foreign corporations to United States shareholders.
U.S. House of Representatives
2021-03-18
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I117th CONGRESS1st SessionH. R. 2031IN THE HOUSE OF REPRESENTATIVESMarch 18, 2021Mr. LaHood (for himself and Mr. Ferguson) introduced the following bill; which was referred to the Committee on Ways and MeansA BILLTo amend the Internal Revenue Code of 1986 to encourage the transfer of intangible property from controlled foreign corporations to United States shareholders.1.Special rules for transfers of intangible property from controlled foreign corporations to United States shareholders(a)In generalSubpart F of part III of subchapter N of chapter 1 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:966.Transfers of intangible property to United States shareholders(a)In generalIf a controlled foreign corporation holds intangible property on the date of the enactment of this section and thereafter distributes such property to a domestic corporation which is a United States shareholder with respect to such controlled foreign corporation—(1)for purposes of part I of subchapter C and any other provision of this title specified by the Secretary, the fair market value of such property on the date of such distribution shall be treated as not exceeding the adjusted basis of such property immediately before such distribution, and(2)if any portion of such distribution is not a dividend—(A)no gain shall be recognized by such United States shareholder with respect to such distribution, and(B)the adjusted basis of such property in the hands of such United States shareholder immediately after such distribution shall be the adjusted basis of such property in the hands of such controlled foreign corporation immediately before such distribution reduced by the amount (if any) of gain not recognized by reason of subparagraph (A) (determined after the application of paragraph (1)).(b)Intangible propertyFor purposes of this section, the term intangible property means any—(1)patent, copyright, license, invention, formula, process, design, pattern, know-how, or format,(2)method, program, system, procedure, campaign, survey, study, forecast, estimate, or technical data,(3)computer software (as defined in section 197(e)(3)(B)), or(4)any similar item, which has substantial value independent of the services of any individual..(b)Conforming amendments(1)Section 197(f)(2)(B)(i) of such Code is amended by inserting 966(a), after 731,.(2)The table of sections for subpart F of part III of subchapter N of chapter 1 of such Code is amended by adding at the end the following new item:Sec. 966. Transfers of intangible property to United States shareholders..(c)Effective dateThe amendments made by this section shall apply to distributions made in taxable years of foreign corporations beginning after December 31, 2021, and to taxable years of United States shareholders in which or with which such taxable years of foreign corporations end.


115 HR 1041 IH: Stop Handouts to Unauthorized Taxpayers Act of 2017
U.S. House of Representatives
2017-02-14
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS1st SessionH. R. 1041IN THE HOUSE OF REPRESENTATIVESFebruary 14, 2017Mr. Bilirakis (for himself and Mr. Jones) introduced the following bill; which was referred to the Committee on Ways and MeansA BILLTo amend the Internal Revenue Code of 1986 to deny the refundable portion of the child tax credit
			 to individuals who are not authorized to be employed in the United States
			 and to terminate the use of certifying acceptance agents to facilitate the
			 application process for ITINs.

 1.Short titleThis Act may be cited as the Stop Handouts to Unauthorized Taxpayers Act of 2017 or the SHUT Act of 2017. 2.Denial of refundable portion of child tax credit to individuals not authorized to be employed in the united states (a)In generalSubsection (d) of section 24 of the Internal Revenue Code of 1986 is amended by inserting after paragraph (2) the following new paragraph:

					(3)Identification requirement with respect to taxpayer
 (A)In generalParagraph (1) shall not apply to any taxpayer for any taxable year unless the taxpayer includes the taxpayer’s social security number on the return of tax for such taxable year or otherwise demonstrates on the return that the taxpayer is authorized to be employed in the United States.
 (B)Joint returnsIn the case of a joint return, the requirement of subparagraph (A) shall be treated as met if either spouse meets such requirement.
 (C)Omission treated as mathematical or clerical errorAny failure to meet the requirement of subparagraph (A) shall be treated as a mathematical or clerical error and assessed according to section 6213(b)(1)..
 (b)Effective dateThe amendments made by this section shall apply to taxable years beginning after the date of the enactment of this Act.
 3.Termination of certifying agent programEffective on the date of the enactment of this Act, no Individual Taxpayer Identification Number may be issued by the Secretary of the Treasury (or any delegate of such Secretary) unless the supporting documentary evidence is submitted to such Secretary or any delegate of such Secretary who is an employee within the Department of the Treasury.


115 HR 1223 IH: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017
U.S. House of Representatives
2017-02-27
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS1st SessionH. R. 1223IN THE HOUSE OF REPRESENTATIVESFebruary 27, 2017Mr. Bilirakis (for himself, Mr. Butterfield, and Mr. McCaul) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo amend the Federal Food, Drug, and Cosmetic Act to authorize an extension of exclusivity periods
			 for certain drugs that are approved for a new indication for a rare
			 disease or condition, and for other purposes.

 1.Short titleThis Act may be cited as the Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 or the OPEN Act. 2.Extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition (a)In generalThe Federal Food, Drug, and Cosmetic Act is amended by inserting after section 505F of such Act (21 U.S.C. 355g) the following:

					505G.Extension of exclusivity periods for a drug approved for a new indication for a rare disease or
			 condition
						(a)Designation
 (1)In generalThe Secretary shall designate a drug as a drug approved for a new indication to prevent, diagnose, or treat a rare disease or condition for purposes of granting the extensions under subsection (b) if—
 (A)prior to approval of an application or supplemental application for the new indication, the drug was approved or licensed under section 505(c) of this Act or section 351(a) of the Public Health Service Act but was not so approved or licensed for the new indication;
								(B)
 (i)the sponsor of the approved or licensed drug files an application or a supplemental application for approval of the new indication for use of the drug to prevent, diagnose, or treat the rare disease or condition; and
 (ii)the Secretary approves the application or supplemental application; and (C)the application or supplemental application for the new indication contains the consent of the applicant to public notice under paragraph (4) with respect to the designation of the drug.
								(2)Revocation of designation
 (A)In generalExcept as provided in subparagraph (B), a designation under paragraph (1) shall not be revoked for any reason.
 (B)ExceptionThe Secretary may revoke a designation of a drug under paragraph (1) if the Secretary finds that the application or supplemental application resulting in such designation contained an untrue statement of material fact.
 (3)Notice to publicThe Secretary shall provide public notice of the designation of a drug under paragraph (1). (b)Extension (1)In generalIf the Secretary designates a drug as a drug approved for a new indication for a rare disease or condition, as described in subsection (a)(1)—
								(A)
 (i)the 4-, 5-, and 7½-year periods described in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 505, the 3-year periods described in clauses (iii) and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) of section 505, and the 7-year period described in section 527, as applicable, shall be extended by 6 months; or
 (ii)the 4- and 12-year periods described in subparagraphs (A) and (B) of section 351(k)(7) of the Public Health Service Act and the 7-year period described in section 527, as applicable, shall be extended by 6 months; and
									(B)
 (i)if the drug is the subject of a listed patent for which a certification has been submitted under subsection (b)(2)(A)(ii) or (j)(2)(A)(vii)(II) of section 505 or a listed patent for which a certification has been submitted under subsection (b)(2)(A)(iii) or (j)(2)(A)(vii)(III) of section 505, the period during which an application may not be approved under section 505(c)(3) or section 505(j)(5)(B) shall be extended by a period of 6 months after the date the patent expires (including any patent extensions); or
 (ii)if the drug is the subject of a listed patent for which a certification has been submitted under subsection (b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) of section 505, and in the patent infringement litigation resulting from the certification the court determines that the patent is valid and would be infringed, the period during which an application may not be approved under section 505(c)(3) or section 505(j)(5)(B) shall be extended by a period of 6 months after the date the patent expires (including any patent extensions).
 (2)Relation to pediatric and qualified infectious disease product exclusivityAny extension under paragraph (1) of a period shall be in addition to any extension of the periods under sections 505A and 505E of this Act and section 351(m) of the Public Health Service Act, as applicable, with respect to the drug.
 (c)LimitationsAny extension described in subsection (b)(1) shall not apply if the drug designated under subsection (a)(1) has previously received an extension by operation of subsection (b)(1).
 (d)DefinitionIn this section, the term rare disease or condition has the meaning given to such term in section 526(a)(2).. (b)ApplicationSection 505G of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies only with respect to a drug for which an application or supplemental application described in subsection (a)(1)(B)(i) of such section 505G is first approved under section 505(c) of such Act (21 U.S.C. 355(c)) or section 351(a) of the Public Health Service Act (42 U.S.C. 262(a)) on or after the date of the enactment of this Act.
			(c)Conforming amendments
 (1)Relation to pediatric exclusivity for drugsSection 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a) is amended— (A)in subsection (b), by adding at the end the following:

 (3)Relation to exclusivity for a drug approved for a new indication for a rare disease or conditionNotwithstanding the references in paragraph (1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in paragraph (1) shall be in addition to any extensions under section 505G.; and
 (B)in subsection (c), by adding at the end the following:  (3)Relation to exclusivity for a drug approved for a new indication for a rare disease or conditionNotwithstanding the references in paragraph (1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in paragraph (1) shall be in addition to any extensions under section 505G..
 (2)Relation to exclusivity for new qualified infectious disease products that are drugsSubsection (b) of section 505E of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355f) is amended—
 (A)by amending the subsection heading to read as follows: Relation to pediatric exclusivity and exclusivity for a drug approved for a new indication for a rare disease or condition.—; and
 (B)by striking any extension of the period under section 505A and inserting any extension of the periods under sections 505A and 505G, as applicable,. (3)Relation to pediatric exclusivity for biological productsSection 351(m) of the Public Health Service Act (42 U.S.C. 262(m)) is amended by adding at the end the following:

						(5)Relation to exclusivity for a biological product approved for a new indication for a rare disease
 or conditionNotwithstanding the references in paragraphs (2)(A), (2)(B), (3)(A), and (3)(B) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in such paragraphs shall be in addition to any extensions under section 505G..


115 HR 1804 IH: Race Horse Cost Recovery Act of 2017
U.S. House of Representatives
2017-03-30
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS1st SessionH. R. 1804IN THE HOUSE OF REPRESENTATIVESMarch 30, 2017Mr. Barr introduced the following bill; which was referred to the Committee on Ways and MeansA BILLTo amend the Internal Revenue Code of 1986 to allow a 3-year recovery period for all race horses.

 1.Short titleThis Act may be cited as the Race Horse Cost Recovery Act of 2017. 2.Three-year depreciation for race horses (a)In generalSection 168(e)(3)(A)(i) of the Internal Revenue Code of 1986 is amended to read as follows:

 (i)any race horse,. (b)Effective dateThe amendments made by this section shall apply to property placed in service after December 31, 2016.


I
112th CONGRESS
2d Session
H. R. 4635
IN THE HOUSE OF REPRESENTATIVES

April 25, 2012
Mr. Altmire introduced the following bill; which was referred to the Committee on Ways and Means

A BILL
To extend the suspension of duty on Phenylisocyanate.

1.Phenylisocyanate
(a)In generalHeading 9902.02.14 of the Harmonized Tariff Schedule of the United States (relating to Phenylisocyanate) is amended by striking the date in the effective period column and inserting 12/31/2015.
(b)Effective dateThe amendment made by this section applies to goods entered, or withdrawn from warehouse for consumption, on or after the 15th day after the date of the enactment of this Act.